Bayer stock: Pharma outlook improves as litigation cash costs persist

Bayer strengthened its 2026 outlook after third-quarter Pharmaceuticals performance exceeded expectations, but litigation-related cash demands remain a central risk for investors. Reuters reported on November 3 that the German group raised its full-year adjusted core earnings forecast after the Pharmaceuticals division delivered sales of 4.68 billion euros.

Bayer also expects a decision before Christmas on a proposed 7.25 billion US dollar settlement covering Roundup claims, according to Reuters. The settlement remains under review by a Missouri state court, and the company continues to face tens of thousands of claims.

Higher targets, persistent cash pressure

Management lifted its currency-adjusted 2026 EBITDA before special items outlook to between 9.8 billion euros and 10.3 billion euros, from 9.6 billion euros to 10.1 billion euros previously. The expected year-end net financial debt range was lowered to between 28 billion euros and 29 billion euros.

The Pharmaceuticals margin outlook was raised to between 25 percent and 27 percent from 23 percent to 25 percent previously. Reuters said the division's third-quarter sales were 5 percent above analysts' expectations, while adjusted group EBITDA reached 1.62 billion euros.

Bayer stock traded at 56.17 euros on Lang & Schwarz at 17:03 CET on Monday, November 9, 2026, 1.06 percent above the Xetra close of Friday, November 6. The move since the latest relevant report adds a separate signal of improved trading sentiment, but does not remove the legal and balance-sheet risks.

What investors watch next

Investors will focus on whether Pharmaceuticals can sustain its growth trajectory while Bayer converts the stronger operating performance into cash. The court process for the proposed Roundup settlement remains another potential milestone before year-end.

The DAX provides the broader German-market context for Bayer stock; see current market reports.

More news and analyses on Bayer stock.